{"schema_version":"secwatch.filing_event.v1","accession":"0001827635-26-000036","form_type":"8-K","ticker":"MANE","cik":"0001827635","company_name":"Veradermics, Inc","filed_at":"2026-10-19T13:06:14+00:00","discovered_at":"2026-10-19T13:07:00.250621+00:00","generated_at":"2026-10-19T13:07:07.189730+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Veradermics VDPHL01 hits all Phase 3 '304' endpoints; TAHC up 28.6-36.4 hairs/cm² vs 6.6 placebo","bullets":["Study '304' randomized 536 males with mild-to-moderate pattern hair loss to VDPHL01 8.5mg once-daily, twice-daily or placebo; all primary and secondary endpoints met (p<0.0001).","Non-vellus target area hair count rose 28.6 hairs/cm² (QD) and 36.4 hairs/cm² (BID) at Month 6 vs 6.6 for placebo; significant separation from placebo seen as early as Month 2.","55.7% (QD) and 68.7% (BID) reported 'improved' or 'much improved' hair coverage on AAIRS vs 15.0% placebo; investigator IGA rated 78.4% and 82.7% improved.","No treatment-related SAEs and no cardiac AESIs; hypertrichosis was the only TEAE >5% with an imbalance (2.2% QD, 9.0% BID); peripheral edema 2.8%/4.5% vs 0.6% placebo.","Part B 12-month data from Study '302' expected later in 2026; female pattern hair loss Study '306' topline anticipated in H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001827635-26-000036","json":"https://secwatch.observer/filing/0001827635-26-000036.json","markdown":"https://secwatch.observer/filing/0001827635-26-000036.md","text":"https://secwatch.observer/filing/0001827635-26-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827635/000182763526000036/0001827635-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827635/000182763526000036/mane-20261019.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-19T13:07:07.189730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}